US6531478B2
(en)
|
2000-02-24 |
2003-03-11 |
Cheryl P. Kordik |
Amino pyrazole derivatives useful for the treatment of obesity and other disorders
|
GB0010757D0
(en)
|
2000-05-05 |
2000-06-28 |
Astrazeneca Ab |
Chemical compounds
|
SE0004462D0
(sv)
|
2000-12-04 |
2000-12-04 |
Pharmacia Ab |
Novel method and use
|
AU2002221222A1
(en)
*
|
2000-12-04 |
2002-06-18 |
Biovitrum Ab |
Novel method and use
|
GB0121941D0
(en)
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
HN2002000266A
(es)
*
|
2001-09-24 |
2003-11-16 |
Bayer Corp |
Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
|
CA2463441A1
(en)
*
|
2001-10-12 |
2003-05-08 |
Bayer Pharmaceuticals Corporation |
Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
|
ES2316777T3
(es)
*
|
2002-02-15 |
2009-04-16 |
Glaxo Group Limited |
Moduladores de receptores vainilloides.
|
US7074805B2
(en)
*
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
WO2004005262A2
(en)
*
|
2002-07-02 |
2004-01-15 |
Schering Corporation |
New neuropeptide y y5 receptor antagonists
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
EP1433788A1
(en)
*
|
2002-12-23 |
2004-06-30 |
Aventis Pharma Deutschland GmbH |
Pyrazole-derivatives as factor Xa inhibitors
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US6933311B2
(en)
*
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
ATE450533T1
(de)
*
|
2003-02-14 |
2009-12-15 |
Glaxo Group Ltd |
Carboxamidderivate
|
JP2006525355A
(ja)
*
|
2003-05-01 |
2006-11-09 |
アボット・ラボラトリーズ |
ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
|
US20040220170A1
(en)
*
|
2003-05-01 |
2004-11-04 |
Atkinson Robert N. |
Pyrazole-amides and sulfonamides as sodium channel modulators
|
JP2006526660A
(ja)
*
|
2003-06-05 |
2006-11-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vr1レセプターのモジュレーター
|
US7015233B2
(en)
*
|
2003-06-12 |
2006-03-21 |
Abbott Laboratories |
Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
|
AU2004260636A1
(en)
*
|
2003-06-13 |
2005-02-10 |
Arena Pharmaceuticals, Inc. |
5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
|
US20050113576A1
(en)
*
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
CA2551037A1
(en)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
TW200533657A
(en)
*
|
2004-02-17 |
2005-10-16 |
Esteve Labor Dr |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
JP2008513426A
(ja)
*
|
2004-09-20 |
2008-05-01 |
バイオリポックス エービー |
炎症の治療に有用なピラゾール化合物
|
ES2325773T5
(es)
|
2004-11-01 |
2014-02-24 |
Amylin Pharmaceuticals, Llc. |
Tratamiento de la obesidad y de los trastornos relacionados
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
US7576099B2
(en)
|
2005-02-28 |
2009-08-18 |
Renovis, Inc. |
Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
|
EP1853610A1
(en)
*
|
2005-03-03 |
2007-11-14 |
Sirtris Pharmaceuticals, Inc. |
N-phenyl benzamide derivatives as sirtuin modulators
|
CA2606760C
(en)
|
2005-05-04 |
2014-12-23 |
Renovis, Inc. |
Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
RU2417985C2
(ru)
|
2005-05-30 |
2011-05-10 |
Баниу Фармасьютикал Ко., Лтд. |
Новые производные пиперидина
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
EP1743890A1
(en)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
|
EP1757587A1
(en)
*
|
2005-07-15 |
2007-02-28 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
EP1743892A1
(en)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios del Dr. Esteve S.A. |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
US7897589B2
(en)
*
|
2005-07-15 |
2011-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
US8093401B2
(en)
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US8088928B2
(en)
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
US7855289B2
(en)
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
WO2007019344A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Sirtris Pharmaceuticals, Inc. |
Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
JPWO2007024004A1
(ja)
|
2005-08-24 |
2009-03-05 |
萬有製薬株式会社 |
フェニルピリドン誘導体
|
EP1939194A4
(en)
|
2005-09-07 |
2010-12-08 |
Banyu Pharma Co Ltd |
AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
TW200800911A
(en)
*
|
2005-10-20 |
2008-01-01 |
Biolipox Ab |
Pyrazoles useful in the treatment of inflammation
|
JP2009512715A
(ja)
|
2005-10-21 |
2009-03-26 |
ノバルティス アクチエンゲゼルシャフト |
レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ
|
CA2627139A1
(en)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
Novel benzoxathiin derivative
|
AU2006310367A1
(en)
*
|
2005-10-31 |
2007-05-10 |
Biolipox Ab |
Triazole compounds as lipoxygenase inhibitors
|
TW200732320A
(en)
*
|
2005-10-31 |
2007-09-01 |
Biolipox Ab |
Pyrazoles useful in the treatment of inflammation
|
WO2007052000A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Biolipox Ab |
Pyrazoles useful in the treatment of inflammation
|
EP1953165B1
(en)
|
2005-11-10 |
2012-02-01 |
Msd K.K. |
Aza-substituted spiro derivative
|
DK2046787T3
(da)
|
2006-08-01 |
2011-07-18 |
Glaxo Group Ltd |
Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
|
CN101541758A
(zh)
*
|
2006-08-25 |
2009-09-23 |
艾博特公司 |
抑制trpv1的吲唑衍生物及其用途
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
CA2664358A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diarylketimine derivative
|
MX2009006730A
(es)
|
2006-12-20 |
2009-06-30 |
Abbott Lab |
Derivados de n-(5, 6, 7, 8-tetrahidronaftalen-1-il) urea y compuestos relacionados como antagonistas de receptor vaniloide trpv1 par el tratamiento de dolor.
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
WO2008123963A1
(en)
|
2007-04-02 |
2008-10-16 |
Renovis, Inc. |
Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
|
ES2427999T3
(es)
|
2007-04-17 |
2013-11-05 |
Evotec Ag |
Compuestos heterocíclicos 2-cianofenil-condensados y composiciones y usos de los mismos
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EA020466B1
(ru)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
|
CL2008001822A1
(es)
|
2007-06-20 |
2009-03-13 |
Sirtris Pharmaceuticals Inc |
Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
|
NZ582057A
(en)
|
2007-07-19 |
2012-03-30 |
Lundbeck & Co As H |
5-membered heterocyclic amides and related compounds
|
WO2009018065A2
(en)
*
|
2007-07-27 |
2009-02-05 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
KR20100092000A
(ko)
*
|
2007-11-01 |
2010-08-19 |
서트리스 파마슈티컬즈, 인코포레이티드 |
시르투인 조절제로서의 아미드 유도체
|
CA2705138A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Sirtris Pharmaceuticals, Inc. |
Solubilized thiazolopyridines
|
EP2262766B1
(en)
|
2008-02-29 |
2015-11-11 |
Evotec AG |
Amide compounds, compositions and uses thereof
|
WO2009110510A1
(ja)
|
2008-03-06 |
2009-09-11 |
萬有製薬株式会社 |
アルキルアミノピリジン誘導体
|
JP2011515414A
(ja)
*
|
2008-03-20 |
2011-05-19 |
アボット・ラボラトリーズ |
Trpv1アンタゴニストである中枢神経系薬剤を作製する方法
|
JPWO2009119726A1
(ja)
|
2008-03-28 |
2011-07-28 |
Msd株式会社 |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
AU2009261248A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2151234A1
(en)
*
|
2008-07-28 |
2010-02-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
|
JPWO2010013595A1
(ja)
|
2008-07-30 |
2012-01-12 |
Msd株式会社 |
5員−5員又は5員−6員縮環シクロアルキルアミン誘導体
|
CN102264228A
(zh)
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
用于抗糖尿病药的新的环状苯并咪唑衍生物
|
JP5635991B2
(ja)
|
2008-10-30 |
2014-12-03 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
イソニコチンアミドオレキシン受容体アンタゴニスト
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
WO2010071853A1
(en)
|
2008-12-19 |
2010-06-24 |
Sirtris Pharmaceuticals, Inc. |
Thiazolopyridine sirtuin modulating compounds
|
WO2010111059A1
(en)
*
|
2009-03-23 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
P2x3 receptor antagonists for treatment of pain
|
US9452980B2
(en)
|
2009-12-22 |
2016-09-27 |
Hoffmann-La Roche Inc. |
Substituted benzamides
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CA2826649C
(en)
|
2011-02-25 |
2016-07-26 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
US20140045746A1
(en)
|
2012-08-02 |
2014-02-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
BR112015019836A2
(pt)
|
2013-02-22 |
2017-07-18 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de um composto
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CN113388007A
(zh)
|
2013-06-05 |
2021-09-14 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3186242B1
(en)
|
2014-08-29 |
2021-10-06 |
Tes Pharma S.r.l. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
DK3356345T3
(da)
|
2015-09-30 |
2024-02-12 |
Max Planck Gesellschaft |
Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
|
WO2017157873A1
(en)
|
2016-03-17 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
|
EP3526199B1
(en)
|
2016-10-14 |
2022-04-13 |
Tes Pharma S.r.l. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
CN113302189A
(zh)
|
2018-11-20 |
2021-08-24 |
Tes制药有限责任公司 |
α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
|
EP3924058A1
(en)
|
2019-02-13 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
WO2021032935A1
(en)
*
|
2019-08-21 |
2021-02-25 |
Kalvista Pharmaceuticals Limited |
Enzyme inhibitors
|
WO2021046515A1
(en)
*
|
2019-09-06 |
2021-03-11 |
Board Of Regents, The University Of Texas System |
Inhibitors of receptor interacting protein kinase i for the treatment of disease
|
EP4034530A4
(en)
|
2019-09-27 |
2023-09-06 |
Board of Regents, The University of Texas System |
PROTEIN KINASE I INHIBITORS INTERACTING WITH RECEPTORS FOR THE TREATMENT OF DISEASE
|
CA3162605A1
(en)
|
2019-11-26 |
2021-06-03 |
Board Of Regents, The University Of Texas System |
Inhibitors of receptor interacting protein kinase i for the treatment of disease
|
JP7443625B2
(ja)
|
2020-08-18 |
2024-03-05 |
メルク・シャープ・アンド・ドーム・エルエルシー |
ビシクロヘプタンピロリジンオレキシン受容体アゴニスト
|